MX2019004992A - Sacubitril valsartán trisódico amorfo y proceso para su preparacion. - Google Patents

Sacubitril valsartán trisódico amorfo y proceso para su preparacion.

Info

Publication number
MX2019004992A
MX2019004992A MX2019004992A MX2019004992A MX2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A MX 2019004992 A MX2019004992 A MX 2019004992A
Authority
MX
Mexico
Prior art keywords
methyl
crystalline form
preparation
present
provides
Prior art date
Application number
MX2019004992A
Other languages
English (en)
Inventor
Venkata Raghavendra Charyulu Palle
Rameshchandra Patel Pratik
Devaiah Venu Thirunelimada
Avathu Vidyasagar Reddy
Shanmughasamy Rajmahendra
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of MX2019004992A publication Critical patent/MX2019004992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona la Forma B1 cristalina de sal sodio de éster etílico del ácido N-(3-carboxil-l-oxopropil)-(4S)-( p- fenilfenilmetil)-4-amino-2R-metil butanoico, la Forma B2 cristalina de sal sodio de éster etílico del ácido N-(3-carboxil-1 -oxopropil)-(4S)-(pfenilfenilmetil)-4-amino-2R-met il butanoico, y un nuevo proceso para la preparación de la Forma B cristalina B de sal sodio de éster etílico del ácido N-(3-carboxil-l-xopropil)-(4S)-(p-fenilfenilmetil)-4-amino-2R- metil butanoico. La presente invención también proporciona la Forma B cristalina de sal disodio de (S)-N-(1-carboxi-2-metil-prop -1-i1)-Npentanoil-N42'-(1H-tetrazol-5-i1)-bifenil-4-il-metil]-ami na, la Forma P cristalina sal disodio de (S)-N-(1-carboxi-2-metil- prop-1-i1)-N-pentanoilN-[2'-(1H-tetrazol-5-i1)-bifenil-4-il-metil ]-amina y procesos para su preparación. La presente invención proporciona además un método industrial de producción de la Forma amorfa de sacubitril valsartán trisódico. La presente invención también proporciona dispersiones sólidas amorfas de sacubitril valsartán trisódico con excipientes.
MX2019004992A 2016-10-28 2017-10-28 Sacubitril valsartán trisódico amorfo y proceso para su preparacion. MX2019004992A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201641037145 2016-10-28
IN201641038689 2016-11-11
IN201641043910 2016-12-22
PCT/IB2017/056706 WO2018078592A1 (en) 2016-10-28 2017-10-28 Amorphous trisodium sacubitril valsartan and process for its preparation

Publications (1)

Publication Number Publication Date
MX2019004992A true MX2019004992A (es) 2020-02-26

Family

ID=62024497

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004992A MX2019004992A (es) 2016-10-28 2017-10-28 Sacubitril valsartán trisódico amorfo y proceso para su preparacion.

Country Status (10)

Country Link
US (2) US10995060B2 (es)
EP (1) EP3532454A4 (es)
JP (1) JP7022747B2 (es)
KR (1) KR20190077467A (es)
AU (1) AU2017349757A1 (es)
BR (1) BR112019008581A2 (es)
CA (1) CA3041962A1 (es)
MX (1) MX2019004992A (es)
RU (1) RU2019115782A (es)
WO (1) WO2018078592A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3840746A1 (en) 2018-08-23 2021-06-30 Novartis AG New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
DE60135560D1 (de) 2000-07-19 2008-10-09 Novartis Ag Valsartan salze
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
CN105461647B (zh) 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
WO2016074651A1 (en) 2014-11-14 2016-05-19 Zentiva, K.S. A method for the preparation, isolation and purification of pharmaceutically applicable forms of ahu-377
CN105693543B (zh) 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN105837464A (zh) * 2015-01-15 2016-08-10 四川海思科制药有限公司 沙库比曲钠的晶型及其制备方法和用途
WO2016125123A1 (en) * 2015-02-06 2016-08-11 Mylan Laboratories Limited Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
WO2017097275A1 (en) 2015-12-11 2017-06-15 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN105503638A (zh) 2016-01-13 2016-04-20 浙江天宇药业股份有限公司 沙库比曲二环己胺盐、晶型及其制备方法

Also Published As

Publication number Publication date
AU2017349757A1 (en) 2019-05-30
JP7022747B2 (ja) 2022-02-18
EP3532454A4 (en) 2020-11-25
BR112019008581A2 (pt) 2019-09-17
US20210122708A1 (en) 2021-04-29
CA3041962A1 (en) 2018-05-03
WO2018078592A1 (en) 2018-05-03
US20190322615A1 (en) 2019-10-24
RU2019115782A (ru) 2020-11-30
RU2019115782A3 (es) 2021-06-17
US11629120B2 (en) 2023-04-18
EP3532454A1 (en) 2019-09-04
US10995060B2 (en) 2021-05-04
KR20190077467A (ko) 2019-07-03
JP2020503257A (ja) 2020-01-30

Similar Documents

Publication Publication Date Title
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
MX2018007129A (es) Formas solidas de ester etilico del acido (2r,4s)-5-(bifenil-4-il) -4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un metodo de preparacion.
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
MX2018003649A (es) Metodos e intermedios para la preparacion de derivados de acido biliar.
MY191236A (en) Diorganylphosphinic acid salts, method for the production thereof and the use thereof
JOP20200059A1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
PH12019501811A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
BR112019001980A2 (pt) inibidor de ido1 e método de preparação e aplicação do mesmo
TN2014000058A1 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
SG11201906688VA (en) Novel ester compounds, method for the production thereof and use thereof
PH12014501711A1 (en) Benzyl sulfonamide derivatives useful as mogat-2 inhibitors
SG10201806830RA (en) Preparation of N,N-(di)alkylaminoalkyl(meth)acrylamide or N,N-(di)alkylaminoalkyl (meth)acrylate and the quaternary ammonium salts thereof as flocculating aids and gelling agents
AU2016237099B2 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
MX2018008966A (es) Procesos mejorados para la preparacion de osimertinib (azd9291) o una sal del mismo y "azd9291 anilina" o una sal del mismo.
MY187899A (en) (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
SG11201810725WA (en) Novel β-lactamase inhibitors
MX2019004992A (es) Sacubitril valsartán trisódico amorfo y proceso para su preparacion.
WO2016142819A3 (en) Novel process for the preparation of ranolazine
MX2019011261A (es) Compuestos de isoxazol carboxamida y sus usos.
PH12016502568B1 (en) Novel heterocyclic compound
PH12017500435A1 (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
PH12017500492A1 (en) Crystalline bace inhibitors